In an insightful interview with Tracy Weslosky, Dave Mehalick, Chairman, President, and CEO of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), delves into the company’s groundbreaking work in cell therapy, particularly against the backdrop of the “tripledemic” of influenza, COVID-19, and respiratory syncytial virus (RSV). Mehalick highlights the success of their phase one clinical trial, which focused on treating hospitalized COVID-19 patients with off-the-shelf natural killer cells, leading to every patient being discharged fully healthy. He emphasizes the potential of this therapy beyond COVID-19, aiming to tackle a wide range of respiratory diseases in future phase two clinical trials.

Mehalick provides an overview of cell therapy’s competitive landscape, explaining how Coeptis’s approach strengthens patients’ immune systems against diseases by using manufactured cells, not derived from the patients themselves. This innovation could revolutionize the treatment of various diseases, particularly respiratory ones.

Additionally, Mehalick discusses the company’s recent news, including a partnership with the University of Pittsburgh to expand the use of SNAP-CAR T and SNAP-CAR NK cells beyond oncology to autoimmune diseases. This expansion is significant, as it leverages the company’s universal cell structure technology, potentially offering a simpler and more cost-effective treatment for autoimmune diseases and cancers.

Mehalick outlines the potential of SNAP-CAR technology to transform the treatment landscape for autoimmune diseases, offering a more accessible and affordable alternative to current CAR-T therapies. This approach could significantly reduce treatment costs and time, making advanced therapies available to a broader patient population. The interview touches on the broader implications of Coeptis’s cell therapy platform, highlighting its potential to disrupt traditional medical treatment modalities globally. To access the full interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis’ business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered in Wexford, PA.

To learn more about Coeptis Therapeutics Holdings, Inc., click here

Disclaimer: Coeptis Therapeutics Holdings, Inc. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.

What’s a company worth to investors that could improve numerous medical conditions related to ischemia (lack of blood flow) and tissue damage, and potentially improve the quality of life? It would be hard to put a price on such a company if they could successfully commercialize or license their product or technology.

Today’s company, Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF | FSE: 2VFO), is having remarkable success, yet due to its early stage has a market cap of only C$19 million. That company is developing methods that use our own bodies’ stem cells to heal certain diseases. The key diseases of focus for now are those revolving around ischemia, such as heart disease, stroke, and diabetic vascular disease and its complications such as limb loss. Over the next year, there will also be a lot of work done on nerve cell regeneration.

Hemostemix Inc. is developing ‘stem cell therapy’ for the treatment of ischemic disease and several other diseases. Hemostemix owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

Results to date have been outstanding, as shown in the image below.

Hemostemix summary of the business and ACP-01

ACP-01 is Hemostemix’s pioneering first stem cell treatment called angiogenic cell precursor (“ACP”).  Hemostemix states: “ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.”

Note: Bold emphasis by the author.

With such stunning success, it is little wonder that Hemostemix is very keen to protect their intellectual property.

On February 14, 2022 Hemostemix announced that they had “been granted International Trademark Registration No. 1624069 for Your Fountain of Youth, a registration that is valid for a period of 10 years.”  Hemostemix further announced on March 23, 2022 that it had resolved outstanding  litigation with a settlement agreement that requires the other parties to return all data and intellectual property in relation to ACP-01 in their possession to Hemostemix.

This is a great outcome for Hemostemix and good news to investors, as the Company believes their ACP-01 intellectual property is incredibly valuable.

Hemostemix has previously published numerous other studies proving the benefit of ACP-01, notably in the treatment of ischemia in various parts of the body. Some examples include improving ischemic cardiomyopathy patients and limb ischemia patients.

Note: NCP stands for Nerve Cell Precursor. CCP stands for Cardiac Cell Precursor. These are cultivated from the patient’s own stem cells using Hemostemix’s patented technologies.

What’s next for Hemostemix?

Apart from further studies, Hemostemix is now looking towards automating production, partnering and commercialization. The goal of improving stem cell production will help lower costs and potentially expand the business. Hemostemix also intends to advance their business development plans including possible licensing of their technology.

To help fund the above, Hemostemix recently announced a $2,750,000 Convertible Debenture offering.

Closing remarks

Hemostemix’s longer-term goal is to support a higher quality of life for all of us, a veritable “fountain of youth”, where we could boost our health yearly with our own stem cells to help repair our bodies.

Hemostemix trades on a market cap of C$19 million. Risk remains high due to the early stage, however there is truly blue sky potential if the Company can successfully license or commercialize their products in future years.